These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

226 related articles for article (PubMed ID: 30377920)

  • 1. ASO Author Reflections: Health Disparities in Pancreatic Cancer.
    Lutfi W; Hogg ME
    Ann Surg Oncol; 2018 Dec; 25(Suppl 3):824-825. PubMed ID: 30377920
    [No Abstract]   [Full Text] [Related]  

  • 2. ASO Author Reflections: Even in Pancreatic Cancer, not all N Diseases are Created Equal.
    Nizri E; Lahat G; Klausner J
    Ann Surg Oncol; 2018 Dec; 25(Suppl 3):804-805. PubMed ID: 30284129
    [No Abstract]   [Full Text] [Related]  

  • 3. ASO Author Reflections: Tumor-Infiltrating Platelets Predict Postsurgical Survival in Patients with Pancreatic Ductal Adenocarcinoma.
    Zhang SR; Li H; Wang WQ; Liu L; Yu XJ
    Ann Surg Oncol; 2018 Dec; 25(13):3994-3995. PubMed ID: 30315385
    [No Abstract]   [Full Text] [Related]  

  • 4. ASO Author Reflections: Do Distinct Patterns of Recurrence Impact the Prognosis of Patients With Resected Pancreatic Ductal Adenocarcinoma?
    Groot VP; Wolfgang CL; He J
    Ann Surg Oncol; 2018 Dec; 25(Suppl 3):806-807. PubMed ID: 30298312
    [No Abstract]   [Full Text] [Related]  

  • 5. ASO Author Reflections: Role of SOX9 Transcription Factor in Pancreatic Neoplasms.
    Turner K; Gnerlich JL
    Ann Surg Oncol; 2019 Dec; 26(Suppl 3):567-568. PubMed ID: 30680476
    [No Abstract]   [Full Text] [Related]  

  • 6. ASO Author Reflections: Tumor-Infiltrating NETs are New Biomarkers to Predict Postsurgical Survival for Patients with Pancreatic Ductal Adenocarcinoma.
    Jin W; Xu HX; Yu XJ; Liu L
    Ann Surg Oncol; 2019 Dec; 26(Suppl 3):571-572. PubMed ID: 30710182
    [No Abstract]   [Full Text] [Related]  

  • 7. ASO Author Reflections: The Naples Prognostic Score Predicts Long-Term Survival in Patients with Resected Pancreatic Cancer.
    Nakagawa N; Yamada S; Kodera Y
    Ann Surg Oncol; 2020 Mar; 27(3):896-897. PubMed ID: 31848821
    [No Abstract]   [Full Text] [Related]  

  • 8. ASO Author Reflections: Re-Excision for Ductal Carcinoma In Situ: Who Is at Risk?
    Lamb LR; Bahl M
    Ann Surg Oncol; 2021 Mar; 28(3):1398-1399. PubMed ID: 32946015
    [No Abstract]   [Full Text] [Related]  

  • 9. ASO Author Reflections: Progression after Resection of Noninvasive or Microinvasive Intraductal Papillary Mucinous Neoplasms.
    Al Efishat M; Allen PJ
    Ann Surg Oncol; 2018 Dec; 25(Suppl 3):822-823. PubMed ID: 30324467
    [No Abstract]   [Full Text] [Related]  

  • 10. ASO Author Reflections: Disparities in NCCN Guideline-Compliant Care for Patients with Early-Stage Pancreatic Adenocarcinoma at Minority-Serving Versus Non-minority-Serving Hospitals.
    Lima HA; Moazzam Z; Pawlik TM
    Ann Surg Oncol; 2023 Jul; 30(7):4373-4374. PubMed ID: 36808592
    [No Abstract]   [Full Text] [Related]  

  • 11. ASO Author Reflections: Lymphocyte-to-monocyte ratio as prognostic biomarker in pancreatic ductal adenocarcinoma.
    Kubota K; Shimizu A; Soejima Y
    Ann Surg Oncol; 2022 Feb; 29(2):1449-1450. PubMed ID: 34618246
    [No Abstract]   [Full Text] [Related]  

  • 12. ASO Author Reflections: Real Prevalence of Occult Cancer Cells in Peritoneal Lavage in Patients with Pancreatic Ductal Adenocarcinoma.
    Suenaga M; Fujii T
    Ann Surg Oncol; 2020 Dec; 27(Suppl 3):893-894. PubMed ID: 32812111
    [No Abstract]   [Full Text] [Related]  

  • 13. ASO Author Reflections: Long-Term Outcomes After Surgical Resection of Pancreatic Metastases from Renal Clear-Cell Carcinoma.
    Malleo G; Salvia R; Allen PJ; Butturini G
    Ann Surg Oncol; 2021 Jun; 28(6):3109-3110. PubMed ID: 33560488
    [No Abstract]   [Full Text] [Related]  

  • 14. ASO Author Reflections: A Standard Set of Value-Based Patient-Centered Outcomes for Pancreatic Carcinoma: An International Delphi Survey.
    Pessaux P; Cherkaoui Z
    Ann Surg Oncol; 2020 Dec; 27(Suppl 3):773-774. PubMed ID: 32495283
    [No Abstract]   [Full Text] [Related]  

  • 15. ASO Author Reflections: Frailty in Pancreatic Cancers.
    Zhang F; Yan Y; Ge C
    Ann Surg Oncol; 2024 Jan; 31(1):545. PubMed ID: 37843665
    [No Abstract]   [Full Text] [Related]  

  • 16. ASO Author Reflections: Unlocking the Value of Inpatient Palliative Care for Patients with Pancreatic Cancer.
    Kim S; Chervu N; Premji A; Mallick S; Verma A; Ali K; Benharash P; Donahue T
    Ann Surg Oncol; 2024 Feb; 31(2):1362-1363. PubMed ID: 38063981
    [No Abstract]   [Full Text] [Related]  

  • 17. ASO Author Reflections: Tumor Biology and Safe Surgery Remain Major Determinants of Survival After Resection of Pancreatic Adenocarcinoma.
    Newhook TE; Tzeng CD
    Ann Surg Oncol; 2021 Mar; 28(3):1570-1571. PubMed ID: 32880772
    [No Abstract]   [Full Text] [Related]  

  • 18. ASO Author Reflections: Identification of Prognostic Factors for Stage-III Pancreatic Ductal Adenocarcinoma patients.
    Chattopadhyay A; Wu CH; Tien YW; Lu TP
    Ann Surg Oncol; 2022 Mar; 29(3):1616-1617. PubMed ID: 34802101
    [No Abstract]   [Full Text] [Related]  

  • 19. ASO Author Reflections: Preceding Systemic Chemotherapy Might Provide Better Prognosis for Pancreatic Ductal Adenocarcinoma with Positive Peritoneal Cytology.
    Ariake K; Mizuma M; Motoi F; Unno M
    Ann Surg Oncol; 2021 Oct; 28(11):6255-6256. PubMed ID: 33634387
    [No Abstract]   [Full Text] [Related]  

  • 20. ASO Author Reflections: Potential Role of Circulating Biomarkers in Resected Pancreatic Adenocarcinoma.
    White MG; Tzeng CD
    Ann Surg Oncol; 2021 Aug; 28(8):4623-4624. PubMed ID: 33507452
    [No Abstract]   [Full Text] [Related]  

    [Next]    [New Search]
    of 12.